Last reviewed · How we verify

NCT03517059: Prodygi-II

Study of Dysarthria, and the Appearance of Non-dopaminergic Signs in Idiopathic PARKinson's Disease

Completed Last updated 23 December 2025
What this trial tests

trial in Parkinson Disease in 29 participants. Completed in 12 November 2018.

Timeline
11 May 2017
Primary endpoint
12 November 2018
12 November 2018

Quick facts

Lead sponsorUniversity Hospital, Lille
StatusCompleted
Study typeOBSERVATIONAL
Enrollment29
Start date11 May 2017
Primary completion12 November 2018
Estimated completion12 November 2018
Sites1 location across France

Conditions studied

Sponsor

University Hospital, Lille

Who can join

Adults 18 to 85, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pilot study: * Longitudinal follow up of the PRODY-GI cohort for parkinson's disease (PD) * Observational study of upper and lower axial symptoms' occurence in 30 PD patients in on and off drug conditions, 30 aged matched control subjects and 10 control subjects with supra nuclear palsy * Multi modal approach: functional MRI, clinical , ENT assessment, respiratory assessment, neuropsychological and gait evaluations

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

Other University Hospital, Lille trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03517059.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing